Even today as we see remarkable developments in the medical field, there are many diseases against which no effective treatment exists. Also, in low- and lower middle-income countries, there are many people who have difficulty receiving necessary medical care due to various reasons such as inadequate medical infrastructure and poverty. Under the corporate philosophy “Dedicated to Man’s Fight against Disease and Pain,” we aim to improve medical access by pursuing these goals: the development of innovative pharmaceutical products, improvement of medical infrastructure, and establishment of partnerships with outside parties. We currently sell our pharmaceutical products ourselves in Japan, South Korea, and Taiwan; in Asia, including Japan, we will make efforts for improving medical access including the treatment of rare diseases. In regions other than Asia, we will make efforts to provide pharmaceuticals with the help of our partner companies. We will also work on supporting medium- to long-term activities to strengthen medical systems by means such as medical education and the development of medical infrastructure through partnerships with NPOs and the Global Health Innovative Technology Fund.
We strive to continually develop innovative drugs through appropriate protection and use of various types of intellectual property generated during the course of drug development, while at the same time respecting intellectual property rights owned by third parties. In some countries, people have difficulty accessing health care due to economic reasons. To deliver our innovative drugs to more patients worldwide, we will neither apply for nor enforce patent rights in Least Developed Countries defined by the United Nations and Low Income Countries defined by the World Bank. We also will not file patent applications or enforce rights in Lower Middle Income Countries defined by the World Bank with the exception of some countries.
The management team oversees the directions for the improvement of medical access and the details of the efforts.
New efforts associated with medical access will be deliberated on and approved by the CSR Committee, chaired by the Corporate Executive Officer / Head of Corporate Communications. Its activities are periodically reported to the Management Meeting which is chaired by the CEO.
Working on the treatment of rare diseases is important so as to improve medical access. We make the following efforts to develop and provide pharmaceuticals for rare diseases.
|Product name||Therapeutic indication||Date designated as an orphan drug||Status|
|OPDIVO intravenous infusion||Malignant melanoma that has no possibility of radical resection||2013.06.17||Approved|
|Recurrent or intractable classical Hodgkin lymphoma||2016.03.16||Approved|
|Progressing or metastatic malignant pleural mesothelioma that has no possibility of radical resection||2017.12.01||Approved|
|Demser Capsules||Mitigation of excess catecholamine secretion in patients with pheochromocytoma||2015.05.25||Approved|
|Kyprolis for intravenous infusion||Recurrent or intractable multiple myeloma||2015.08.20||Approved|
|Onoact for intravenous infusion||The kinds of life-threatening cardiac arrhythmia in intractable and urgent cases: ventricular fibrillation and hemodynamically unstable ventricular tachycardia||2016.08.24||Approved|
|Mektovi Tablets||Treatment of unresectable malignant melanoma with a BRAF mutation||2018.03.30||Approved|
|Braftovi Capsules||Treatment of unresectable malignant melanoma with a BRAF mutation||2018.03.30||Approved|
|Velexbru||Primary central nervous system lymphoma (PCNSL)||2019.08.20||Approved|
|Waldenstrom macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL)||2019.11.19||Under development|
In addition, Opdivo is designated as a target item under the Priority Assessment Designation System, specified by the Ministry of Health, Labour and Welfare, that targets bile duct cancer.
Medication evaluated appropriately for children should be used for pediatric patients. Aiming to improve pediatric patients’ access to healthcare products, we are working on the flexible approval for children as follows.
|Product name||Pharmaceutical indication||Status|
|Onon Dry Syrup||Bronchial asthma and allergic rhinitis||Approved|
|Emend Capsules||Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including the delayed phase)||Approved|
|Proemend for intravenous injection.||Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic agents (cisplatin, etc.) (including the delayed phase)||Approved|
|Orencia for intravenous infusion||Active polyarticular juvenile idiopathic arthritis||Approved|
|Onoact for intravenous infusion||Tachyarrhythmia in cases of cardiac function failure||Under development|
Together with Keio University, Kochi University, the National Institute of Biomedical Innovation, Health and Nutrition, Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Co., Ltd., we established the Immune-mediated Inflammatory Diseases Consortium for Drug Development for the purpose of drug development research targeting intractable immuno inflammatory diseases in May 2018. It is expected that the achievements of this consortium will lead to the creation of next-generation pharmaceuticals with high utility against intractable immunoinflammatory diseases and also enable the provision of new treatment options for patients and healthcare professionals.
As an effort made to promote both Work Style Reform and activities to contribute to society, we started ONO SWITCH Project in August 2018. This effort is an effort to make donations to NPOs/NGOs related to medical care using the money saved through the reduction of overtime work through the promotion of Work Style Reform, aiming to further promote the embodiment of the corporate philosophy “Dedicated to Man’s Fight against Disease and Pain" by contributing to the promotion of working style reform and healthcare and people’s health around the world.
The project was named by abbreviating Save the World by our work style ImprovemenT and CHange (meaning saving the world through improvement and reform of our ways of working). The project name also expresses switching work methods to new ones, switching the funds obtained through working style reform to donation, and switching on the process of reexamining how to work.
Recipients: We donated to the following NPOs based on responses to questionnaires targeting all our employees.
|Partner||Description of efforts made||Area of operation|
|1||Nanbyo no Kodomo Shien Zenkoku Network(Nation-wide Network to Support Children with Intractable Disease)||
|2||Vaccines for the World’s Children||
In this project, we will work on improving access to healthcare products and improving medical infrastructure through partnerships with outside parties.
|1||Nanbyo no Kodomo Shien Zenkoku Network (Nationwide Network to Support Children with Intractable Diseases)||To hold symposia to promote understanding of intractable diseases.||
|2||Vaccines for the World’s Children||To provide DPT vaccines and hepatitis B vaccines to be used in Bhutan throughout the year.
To start developing an infrastructure for cold chains (a system to transport vaccines at low temperatures to points of consumption).
|Funds were contributed for the provision of DPT vaccines and hepatitis B vaccines to be used in Bhutan next fiscal year as well as Ice Line coolers for refrigerating the vaccines.|
|3||Japan Heart||To provide one person with healthcare professional education every year.
To have 100 people receive healthcare professional education.
Training in neonatal cardiopulmonary resuscitation was provided to 24 local medical professionals.
We became a member company of the Global Health Innovative Technology Fund (GHIT Fund) in 2018. The GHIT Fund is an international, non-profit organization that invests in the development of new drugs against various diseases such as malaria and tuberculosis, other less marketable drugs against neglected tropical diseases and other minor diseases, vaccines, and diagnostic agents, and is funded by the Japanese government, the Bill & Melinda Gates Foundation, the Welcome Trust, and private enterprises in Japan and overseas. In order to reduce the health disparities between developed countries and low- and middle-income countries, the therapeutic agents, vaccines, and diagnostic agents developed through the GHIT Fund's investments are priced according to the “No Gain, No Loss” principle. We understand the efforts and policy, and we contribute to the funding of the GHIT Fund. Through participation in the GHIT Fund, we will strengthen the establishment of partnerships aiming to improve medical access in low- and middle-income countries.
"Dedicated to Man’s Fight against Disease and Pain" is our corporate philos...
Basic Policy Examples of working on the creation of pharmaceutical...
Even today as we see remarkable developments in the medical field, there ar...
Efforts made against rare diseases Working on the treatment of rare dise...
ONO SWITCH Project As an effort made to promote both Work Style Reform a...
Development of Human Resources Respect for Human Rights Diversit...
Concept of Human Resource Development We aim to develop human resources ...
We respect everyone’s human rights in all business activities. We do not a...
ONO considers that it is important to diversify the characteristics, values...
Enhancing Cultivation of Employee-friendly Workplaces Efforts made...
ONO is moving ahead to create workplaces where employees can work with a se...
Health Up Declaration 2018 Based on our corporate philosophy, Ded...
Supporting disease prevention, early detection and early treatment ...
Promoting CSR in procurement Animal experiment outsourcing policy ...
ONO believes that it is important to build a sound network with all busines...
When we outsource animal experiments, we ensure that the outsourcing contra...
Before appointing a third party such as a subcontractor or an agent, we per...